The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation

Blood

Volumn 95, Issue 9, 2000, Pages 2975-2982

  Breuer, William ^a   Ronson, Aharon ^b   Slotki, Itzchak N ^b   Abramov, Ayala ^b   Hershko, Chaim ^b   Cabantchik, Z Ioav ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON;

ADOLESCENT; ANEMIA; APLASIA; ARTICLE; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; IRON THERAPY; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SCHOOL CHILD; THALASSEMIA;

EID: 0034193128     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.9.2975.009k03_2975_2982     Document Type: Article

References (23)

1. Hershko H, Graham G, Bates GW, Rachmilewitz E. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40:255-263.
2. Ahmed NK, Hanna M, Wang W. Nontransferrin-bound serum iron in thalassemia and sickle cell patients. Int J Biochem. 1986;18:953-956.
3. Singh S, Hider RC, Porter JB. A direct method tor quantification of non-transferrin-bound iron. Anal Biochem. 1990;186:320-323.
4. Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycin detectable iron in serum from leukaemic patients before and after chemotherapy. FEBS Lett. 1988;241:202-204.
5. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol. 1997;99:337-343.
6. Gutteridge JMC. Iron and oxygen radicals in heart and lung damage. Proceedings of The Roles of Free Radicals in Health and Disease. Jerusalem, Israel, March 22-27;1998:40.
7. Breuer W, Epsztejn S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem. 1995;270:24,209-24,215.
8. Cabantchik ZI, Milgram P, Glickstein H, Breuer W. A method for assessing iron chelation in membrane model systems and in living mammalian cells. Anal Biochem. 1995;233:221-227.
9. Epsztejn S, Kakhlon O, Breuer W, Glickstein H, Cabantchik ZI. A fluorescence assay for the labile iron pool (LIP) of mammalian cells. Anal Biochem. 1997;248:31-40.
10. Pollack S, Vanderhoff G, Lasky F. Iron removal from transferrin - an experimental study. Biochim Biophys Acta. 1977;497:481-487.
11. Keberle H The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758-768.
12. Aisen P, Aasa R, Redfield AG. The Cr, Mn and Co complexes of transferrin. J Biol Chem. 1969;244: 4628-4633.
13. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88:705-713.
14. al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol. 1992;82:431-436
15. Evans PJ, Halliwell B. Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. Methods Enzymol. 1994;233:82-89.
16. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron chelators as antimalarials. The combined action of desferrioxamine and arylisonicotinoyl-hydrazones. J Lab Clin Med. 1996; 127:574-582.
17. van Landeghem GF, D'Haese PC, Lamberts LV, et al. Low serum aluminum values in dialysis patients with increased bone aluminum levels. Clin Nephrol. 1998;50:69-76.
18. Montenegro J, Aguirre R, Saracho R, Moina I, Martinez I. Factors influencing serum aluminum in CAPD patients. Clin Nephrol. 1998;50:77-83.
19. Soldado-Cabezuelo AB, Montes-Bayon M, Blancon-Gonzalez E, Garcia-Alonzo JI, Sanz-Medel A. Speciation of basal aluminum in human serum by fast protein liquid chromatography with inductively coupled plasma mass spectrometric detection. Analyst. 1998;123:865-869
20. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998;97:1461-1466.
21. Eschbach JW, Adamson JW. Iron-overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int. 1999; 55:S35-S43.
22. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of non-transferrin bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999;273:212-220.
23. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin bound iron in plasma or serum from patients with idiopathic hemochromatosis. J Biol Chem. 1989;264:4417-4422.